EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG Announces Details of the Capital Increase

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Restructuring & Recapitalisations/Company Information/molecular
diagnostics 07.01.2013

Not for distribution in the United States

Berlin, Germany, January 7, 2013 - Today the Executive Board of
Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN:
DE000A1K0516), with the approval of the Supervisory Board, resolved
to increase the issued share capital from EUR 8,818,417.00 by up to
EUR 3,149,430.00 up to EUR 11,967,847.00 by issuing up to 3,149,430
new ordinary bearer shares with no-par value, each such share
representing a notional nominal amount of the issued share capital of
EUR 1.00 per share against cash contributions utilizing authorized
capital.

The capital increase is structured as an indirect rights issue
conducted by Kempen&Co. The new shares will be offered to the
Company's shareholders at a ratio of 14 (existing shares):5 (new
shares) at a subscription price of EUR 1.58 per new share. In
addition, the shareholders will be offered the possibility to
subscribe for additional shares (oversubscription).

The subscription offer is expected to be published on the Company's
website (www.epigenomics.com) and in the German Federal Gazette
(Bundesanzeiger) on January 10, 2013. The subscription period for the
Company's shareholders is expected to begin on January 11, 2013 and
to end on January 24, 2013 (in each case including such dates). The
new shares carry full dividend rights as from January 1, 2012.

Shares not subscribed for by shareholders might subsequently be
offered in a private placement to institutional investors subject to
selling restrictions as may be applicable in certain jurisdictions.
The actual number eventually issued under the capital increase is
determined following the end of the subscription period and the take
up under the private placement.

The capital increase is structured in a manner that the gross
proceeds generated by it will at a maximum be equal to an amount just
short of EUR 5,000,000, but will not reach that amountso that the
capital increase does not require a prospectus under German law.The
amount of the gross proceeds actually generated depends on the number
of new shares eventuallysubscribed for or taken up under the private
placement and may therefore fall more or less short of the envisaged
maximum amount.

Epigenomics AG intends to use the net proceeds from the offering to
finance its current operations.

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a
solicitation of an offer to purchase securities in the United States.
The shares of Epigenomics AG (the "Shares") have not been registered
under the U.S. Securities Act of 1933, as amended (the "Securities
Act") and may not be offered or sold in the United States unless
registered under the Securities Act or pursuant to an exemption from
such registration. There will be no public offering of the Shares in
the United States and the Shares will not be registered under the
Securities Act.

Contact:

Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English